This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO I-O 2019 – RECK POSTER

Nintedanib plus docetaxel after immunotherapy in adenocarcinoma non-small cell lung cancer: first results from the non-interventional LUME-BioNIS study

Reck M, Syrigos K, Miliauskas S, Zöchbauer-Müller S, Buchner H, Kitzing T, Kerr K

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

ESMO I-O 2019  RECK POSTER

Related articles

Learn more about the efficacy and safety of nintedanib* plus docetaxel in this setting below

Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma

Grohé C, et al. Future Oncol 2019;15(23):2699–706.

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib named patient use program

Corral J, et al. Clin Transl Oncol 2019;21(9):1270–9.

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

 

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: December 2019